Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Gland Pharma Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 2:01 pm

Market Cap 27,045 Cr.
Current Price 1,642
High / Low 2,221/1,411
Stock P/E24.1
Book Value 557
Dividend Yield1.22 %
ROCE16.7 %
ROE12.3 %
Face Value 1.00
PEG Ratio10.80

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Gland Pharma Ltd

Competitors of Gland Pharma Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Gland Pharma Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 1,0631,1038571,0489267858841,0111,0981,1751,0121,0631,011
Expenses 714755587753642616625664728742718699620
Operating Profit 349348270295284169259347369433294364391
OPM % 33%32%32%28%31%22%29%34%34%37%29%34%39%
Other Income 4665746662-1835414347485865
Interest 12123221151018
Depreciation 28313537383839404043414244
Profit before tax 366381309322305112254347372433300380394
Tax % 25%25%26%26%25%29%26%26%26%26%26%26%25%
Net Profit 27328622924022879188258277321223282295
EPS in Rs 16.6417.4113.9414.5513.824.8111.3915.6416.8119.5113.5317.1017.91

Last Updated: February 28, 2025, 7:50 pm

Below is a detailed analysis of the quarterly data for Gland Pharma Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹1,011.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,063.00 Cr. (Sep 2024) to ₹1,011.00 Cr., marking a decrease of 52.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹620.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 699.00 Cr. (Sep 2024) to ₹620.00 Cr., marking a decrease of 79.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹391.00 Cr.. The value appears strong and on an upward trend. It has increased from 364.00 Cr. (Sep 2024) to ₹391.00 Cr., marking an increase of ₹27.00 Cr..
  • For OPM %, as of Dec 2024, the value is 39.00%. The value appears strong and on an upward trend. It has increased from 34.00% (Sep 2024) to 39.00%, marking an increase of 5.00%.
  • For Other Income, as of Dec 2024, the value is ₹65.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Sep 2024) to ₹65.00 Cr., marking an increase of ₹7.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹18.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Sep 2024) to ₹18.00 Cr., marking an increase of ₹18.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹44.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 42.00 Cr. (Sep 2024) to ₹44.00 Cr., marking an increase of ₹2.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹394.00 Cr.. The value appears strong and on an upward trend. It has increased from 380.00 Cr. (Sep 2024) to ₹394.00 Cr., marking an increase of ₹14.00 Cr..
  • For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Sep 2024) to 25.00%, marking a decrease of 1.00%.
  • For Net Profit, as of Dec 2024, the value is ₹295.00 Cr.. The value appears strong and on an upward trend. It has increased from 282.00 Cr. (Sep 2024) to ₹295.00 Cr., marking an increase of ₹13.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 17.91. The value appears strong and on an upward trend. It has increased from ₹17.10 (Sep 2024) to 17.91, marking an increase of ₹0.81.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:13 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 7559919941,3481,4791,6202,0442,6333,4634,4013,6174,1674,261
Expenses 5196306788458541,0851,3381,6782,1612,8902,5982,7582,779
Operating Profit 2363613165026255357069551,3021,5111,0191,4101,481
OPM % 31%36%32%37%42%33%35%36%38%34%28%34%35%
Other Income 593037344966139135224184166218
Interest 131317166447357824
Depreciation 152857637478829599110147162169
Profit before tax 2133272724595785026869931,3351,6191,0481,4051,507
Tax % 26%32%23%32%28%36%34%22%25%25%26%26%
Net Profit 1582242093144143214527739971,2127761,0431,121
EPS in Rs 134.45190.40133.53202.40267.01207.24291.6549.8860.9473.7847.1163.3468.05
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%32%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)41.77%-6.70%50.24%31.85%-22.46%40.81%71.02%28.98%21.56%-35.97%34.41%
Change in YoY Net Profit Growth (%)0.00%-48.47%56.94%-18.39%-54.31%63.27%30.21%-42.04%-7.41%-57.54%70.38%

Gland Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:15%
5 Years:15%
3 Years:6%
TTM:13%
Compounded Profit Growth
10 Years:17%
5 Years:18%
3 Years:2%
TTM:34%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:-22%
1 Year:-7%
Return on Equity
10 Years:16%
5 Years:16%
3 Years:14%
Last Year:12%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 11:41 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 12121615161616161616161616
Reserves 5988221,3791,6622,0742,3952,8473,6315,8877,1427,9378,9799,157
Borrowings 123176166117665555443
Other Liabilities 187277197292378512655435588671815542737
Total Liabilities 9201,2871,7582,0862,4742,9283,5234,0866,4967,8348,7739,5419,913
Fixed Assets 3094606497888728439299689541,5021,5711,6941,673
CWIP 202208192202161199123188338191177120129
Investments 00000000116382,3862,790
Other Assets 4096199171,0961,4411,8872,4712,9295,2035,9787,0175,3425,322
Total Assets 9201,2871,7582,0862,4742,9283,5234,0866,4967,8348,7739,5419,913

Below is a detailed analysis of the balance sheet data for Gland Pharma Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹16.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹9,157.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹8,979.00 Cr. (Mar 2024) to ₹9,157.00 Cr., marking an increase of 178.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹3.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹4.00 Cr. (Mar 2024) to ₹3.00 Cr., marking a decrease of 1.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹737.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹542.00 Cr. (Mar 2024) to ₹737.00 Cr., marking an increase of 195.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹9,913.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹9,541.00 Cr. (Mar 2024) to ₹9,913.00 Cr., marking an increase of 372.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹1,673.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,694.00 Cr. (Mar 2024) to ₹1,673.00 Cr., marking a decrease of 21.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹129.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹120.00 Cr. (Mar 2024) to ₹129.00 Cr., marking an increase of 9.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹2,790.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,386.00 Cr. (Mar 2024) to ₹2,790.00 Cr., marking an increase of 404.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹5,322.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹5,342.00 Cr. (Mar 2024) to ₹5,322.00 Cr., marking a decrease of 20.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹9,913.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹9,541.00 Cr. (Mar 2024) to ₹9,913.00 Cr., marking an increase of 372.00 Cr..

Notably, the Reserves (₹9,157.00 Cr.) exceed the Borrowings (3.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow113.00185.00150.00385.00619.00529.00701.00950.00-4.00-4.00-3.00-3.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days626262951031079083718987103
Inventory Days169229283248271283388250312205421253
Days Payable5774586013616119082978012859
Cash Conversion Cycle174217288283239229289251286214381296
Working Capital Days70100141155154185191161169168241224
ROCE %36%39%22%28%30%22%27%30%28%25%15%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters58.00%57.87%57.86%57.86%57.86%57.86%57.86%57.86%57.86%51.83%51.83%51.83%
FIIs10.72%9.41%6.10%4.67%4.33%2.80%4.91%4.05%3.59%6.88%4.48%5.04%
DIIs12.46%17.36%21.92%23.13%23.23%23.38%22.45%24.17%25.23%32.83%35.37%34.80%
Public18.82%15.35%14.13%14.35%14.59%15.97%14.78%13.93%13.32%8.46%8.33%8.33%
No. of Shareholders1,09,0981,17,3391,27,8791,48,4691,50,5781,81,7471,61,6271,36,0211,22,3751,22,6651,22,3581,21,075

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Mirae Asset Emerging Bluechip Fund3,271,2281.8505.731,416,4372025-03-11130.95%
Mirae Asset Large Cap Fund2,337,9061.05361.441,416,4372025-03-1165.06%
Mirae Asset Tax Saver Fund2,047,1141.81316.481,416,4372025-03-1144.53%
SBI Large & Midcap Fund2,000,0001.98309.21,416,4372025-03-1141.2%
Nippon India Small Cap Fund1,696,9330.7262.351,416,4372025-03-1119.8%
Mirae Asset Focused Fund1,580,3112.82244.321,416,4372025-03-1111.57%
Nippon India Pharma Fund1,500,0004.19231.91,416,4372025-03-115.9%
Nippon India Multi Cap Fund1,416,4371.05218.981,416,4372025-03-110%
SBI Magnum Global Fund1,300,0003.28200.981,416,4372025-03-11-8.22%
HDFC Large and Mid Cap Fund - Regular Plan1,105,8001.44170.961,416,4372025-03-11-21.93%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 46.9047.4473.8163.0749.88
Diluted EPS (Rs.) 46.9047.4373.8162.9949.88
Cash EPS (Rs.) 67.8256.3380.4666.9855.98
Book Value[Excl.RevalReserv]/Share (Rs.) 529.65483.23435.64360.86235.32
Book Value[Incl.RevalReserv]/Share (Rs.) 529.65483.23435.64360.86235.32
Revenue From Operations / Share (Rs.) 343.92220.07267.85211.68169.94
PBDIT / Share (Rs.) 91.2776.82105.5487.8470.64
PBIT / Share (Rs.) 70.3567.9198.8381.8064.54
PBT / Share (Rs.) 68.7664.0398.5181.5964.08
Net Profit / Share (Rs.) 46.9047.4273.7560.9449.88
NP After MI And SOA / Share (Rs.) 46.9047.4273.7560.9449.88
PBDIT Margin (%) 26.5334.9039.4041.4941.56
PBIT Margin (%) 20.4530.8536.8938.6437.97
PBT Margin (%) 19.9929.0936.7738.5437.70
Net Profit Margin (%) 13.6321.5427.5328.7929.35
NP After MI And SOA Margin (%) 13.6321.5427.5328.7929.35
Return on Networth / Equity (%) 8.859.8116.9216.8821.19
Return on Capital Employeed (%) 12.5013.8922.3922.3626.83
Return On Assets (%) 7.248.8915.4615.3418.91
Long Term Debt / Equity (X) 0.010.000.000.000.00
Total Debt / Equity (X) 0.030.000.000.000.00
Asset Turnover Ratio (%) 0.580.430.610.650.00
Current Ratio (X) 4.049.4610.0510.007.93
Quick Ratio (X) 2.856.808.027.515.82
Inventory Turnover Ratio (X) 1.251.101.661.720.00
Interest Coverage Ratio (X) 57.38169.90330.81421.28152.41
Interest Coverage Ratio (Post Tax) (X) 30.48113.46232.15293.28108.61
Enterprise Value (Cr.) 28818.2817126.9950622.6337532.510.00
EV / Net Operating Revenue (X) 5.094.7311.5010.840.00
EV / EBITDA (X) 19.1713.5429.1926.120.00
MarketCap / Net Operating Revenue (X) 5.365.7612.2111.710.00
Price / BV (X) 3.482.637.506.870.00
Price / Net Operating Revenue (X) 5.365.7612.2111.710.00
EarningsYield 0.020.030.020.020.00

After reviewing the key financial ratios for Gland Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 47.44 (Mar 23) to 46.90, marking a decrease of 0.54.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 47.43 (Mar 23) to 46.90, marking a decrease of 0.53.
  • For Cash EPS (Rs.), as of Mar 24, the value is 67.82. This value is within the healthy range. It has increased from 56.33 (Mar 23) to 67.82, marking an increase of 11.49.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 529.65. It has increased from 483.23 (Mar 23) to 529.65, marking an increase of 46.42.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 529.65. It has increased from 483.23 (Mar 23) to 529.65, marking an increase of 46.42.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 343.92. It has increased from 220.07 (Mar 23) to 343.92, marking an increase of 123.85.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 91.27. This value is within the healthy range. It has increased from 76.82 (Mar 23) to 91.27, marking an increase of 14.45.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 70.35. This value is within the healthy range. It has increased from 67.91 (Mar 23) to 70.35, marking an increase of 2.44.
  • For PBT / Share (Rs.), as of Mar 24, the value is 68.76. This value is within the healthy range. It has increased from 64.03 (Mar 23) to 68.76, marking an increase of 4.73.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 47.42 (Mar 23) to 46.90, marking a decrease of 0.52.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 47.42 (Mar 23) to 46.90, marking a decrease of 0.52.
  • For PBDIT Margin (%), as of Mar 24, the value is 26.53. This value is within the healthy range. It has decreased from 34.90 (Mar 23) to 26.53, marking a decrease of 8.37.
  • For PBIT Margin (%), as of Mar 24, the value is 20.45. This value exceeds the healthy maximum of 20. It has decreased from 30.85 (Mar 23) to 20.45, marking a decrease of 10.40.
  • For PBT Margin (%), as of Mar 24, the value is 19.99. This value is within the healthy range. It has decreased from 29.09 (Mar 23) to 19.99, marking a decrease of 9.10.
  • For Net Profit Margin (%), as of Mar 24, the value is 13.63. This value exceeds the healthy maximum of 10. It has decreased from 21.54 (Mar 23) to 13.63, marking a decrease of 7.91.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 13.63. This value is within the healthy range. It has decreased from 21.54 (Mar 23) to 13.63, marking a decrease of 7.91.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 8.85. This value is below the healthy minimum of 15. It has decreased from 9.81 (Mar 23) to 8.85, marking a decrease of 0.96.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 12.50. This value is within the healthy range. It has decreased from 13.89 (Mar 23) to 12.50, marking a decrease of 1.39.
  • For Return On Assets (%), as of Mar 24, the value is 7.24. This value is within the healthy range. It has decreased from 8.89 (Mar 23) to 7.24, marking a decrease of 1.65.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 23) to 0.01, marking an increase of 0.01.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.03. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.03, marking an increase of 0.03.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.58. It has increased from 0.43 (Mar 23) to 0.58, marking an increase of 0.15.
  • For Current Ratio (X), as of Mar 24, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 9.46 (Mar 23) to 4.04, marking a decrease of 5.42.
  • For Quick Ratio (X), as of Mar 24, the value is 2.85. This value exceeds the healthy maximum of 2. It has decreased from 6.80 (Mar 23) to 2.85, marking a decrease of 3.95.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.25. This value is below the healthy minimum of 4. It has increased from 1.10 (Mar 23) to 1.25, marking an increase of 0.15.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 57.38. This value is within the healthy range. It has decreased from 169.90 (Mar 23) to 57.38, marking a decrease of 112.52.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 30.48. This value is within the healthy range. It has decreased from 113.46 (Mar 23) to 30.48, marking a decrease of 82.98.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 28,818.28. It has increased from 17,126.99 (Mar 23) to 28,818.28, marking an increase of 11,691.29.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 5.09. This value exceeds the healthy maximum of 3. It has increased from 4.73 (Mar 23) to 5.09, marking an increase of 0.36.
  • For EV / EBITDA (X), as of Mar 24, the value is 19.17. This value exceeds the healthy maximum of 15. It has increased from 13.54 (Mar 23) to 19.17, marking an increase of 5.63.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.36. This value exceeds the healthy maximum of 3. It has decreased from 5.76 (Mar 23) to 5.36, marking a decrease of 0.40.
  • For Price / BV (X), as of Mar 24, the value is 3.48. This value exceeds the healthy maximum of 3. It has increased from 2.63 (Mar 23) to 3.48, marking an increase of 0.85.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.36. This value exceeds the healthy maximum of 3. It has decreased from 5.76 (Mar 23) to 5.36, marking a decrease of 0.40.
  • For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Gland Pharma Ltd as of March 12, 2025 is: ₹1,337.01

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Gland Pharma Ltd is Overvalued by 18.57% compared to the current share price 1,642.00

Intrinsic Value of Gland Pharma Ltd as of March 12, 2025 is: 1,366.85

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Gland Pharma Ltd is Overvalued by 16.76% compared to the current share price 1,642.00

Last 5 Year EPS CAGR: 2.23%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 26.58%, which is a positive sign.
  2. The company has higher reserves (4,193.08 cr) compared to borrowings (48.08 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (212.69 cr) and profit (310.38 cr) over the years.
  1. The stock has a high average Working Capital Days of 163.25, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 262.25, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gland Pharma Ltd:
    1. Net Profit Margin: 13.63%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 12.5% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 8.85% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 30.48
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.85
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 24.1 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.03
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company's Total Operating Revenue is Rs. 4167.43 Cr. and Equity Capital is Rs. 16.47 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSy.No. 143-148, 150 & 151, Hyderabad Telangana 500043investors@glandpharma.com
https://www.glandpharma.com
Management
NamePosition Held
Mr. Yiu Kwan Stanley LauChairman & Ind.Director
Mr. Srinivas SaduManaging Director & CEO
Mr. Yao FangNon Executive Director
Dr. Jia Ai (Allen) ZhangNon Executive Director
Mr. Qiyu ChenNon Executive Director
Mr. Essaji Goolam VahanvatiIndependent Director
Mr. Udo Johannes VetterIndependent Director
Mr. Satyanarayana Murthy ChavaliIndependent Director
Ms. Naina Lal KidwaiIndependent Director

FAQ

What is the latest intrinsic value of Gland Pharma Ltd?

The latest intrinsic value of Gland Pharma Ltd as on 10 March 2025 is ₹1337.01, which is 18.57% lower than the current market price of 1,642.00, indicating the stock is overvalued by 18.57%. The intrinsic value of Gland Pharma Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹27,045 Cr. and recorded a high/low of ₹2,221/1,411 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹9,157 Cr and total liabilities of ₹9,913 Cr.

What is the Market Cap of Gland Pharma Ltd?

The Market Cap of Gland Pharma Ltd is 27,045 Cr..

What is the current Stock Price of Gland Pharma Ltd as on 10 March 2025?

The current stock price of Gland Pharma Ltd as on 10 March 2025 is ₹1,642.

What is the High / Low of Gland Pharma Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Gland Pharma Ltd stocks is ₹2,221/1,411.

What is the Stock P/E of Gland Pharma Ltd?

The Stock P/E of Gland Pharma Ltd is 24.1.

What is the Book Value of Gland Pharma Ltd?

The Book Value of Gland Pharma Ltd is 557.

What is the Dividend Yield of Gland Pharma Ltd?

The Dividend Yield of Gland Pharma Ltd is 1.22 %.

What is the ROCE of Gland Pharma Ltd?

The ROCE of Gland Pharma Ltd is 16.7 %.

What is the ROE of Gland Pharma Ltd?

The ROE of Gland Pharma Ltd is 12.3 %.

What is the Face Value of Gland Pharma Ltd?

The Face Value of Gland Pharma Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gland Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE